It has been shown that a new approach from radio-immunotherapy successfully eliminates cancer stem cells (CSC) in pre-cancering ovarian cancer models, outperforming the current gold stallion. This research, published in the July issue of Le Journal of Nuclear Medicinelays the basis of a subsequent development of radionuclides therapies targeting CSC, offering renewed hope for more effective treatment options and improved results for patients.
CSCs are very tumorigenic and self-renewable cells that play a key role in tumor relapse, metastases and resistance to therapy. Although the clinical meaning of CSC elimination is clearly recognized and CSC immunotherapy has been examined in preclinical and clinical assessments, the development of such therapies remains a challenge.
Radio-immun therapy allows the precise and specific administration of the target of particular radiation to antigens associated with cancer, while minimizing the outside target accumulation and increasing the retention and irradiation of tumors, making it a promising choice to target CSC. Our study sought to study the effectiveness of a new Radionuclide Terbium-161 (161TB) for the eradication of CSCs due to the short-term conversion emission and the electrons of Cière-Betaid-Moins the ovarian CSCs who succeeded in the lutetium-77 (177Lu). «
Jürgen Grünberg, PhD, scientifique principal au Center for Radiopharmaceutical Sciences, Center for Life Sciences au Paul Scherrer Institute in Willing, suisse
The researchers identified biomarkers associated with the CSC (L1Cam+/ CD133+) In a sample of ovary cancer, then created radio -marked immunoconjugated with 177Lu you 161TB to target these CSCs. The cytotoxicity of radio-immunoconstone (177Lu-Dota-Christ7 and 161TB-DOTA -CHCE7) was measured by in vitro cell proliferation tests and in models of xenogreffered mouse in vivo.
161TB-DOTA -CHCE7 has shown significantly increased cytotoxicity, compared to 177Lu-Dota-Christ7, eliminating all the Ovarian and tumor cells differentiated from CSC in vivo.
“It means a central step towards the translation of 161Therapies based on tuberculosis in the clinical application, “Tihomir Todorov, PHD, junior scientist at the Center for Radiopharmaceutical Sciences, Center for Life Sciences of the Paul Scherrer Institute. 161Tuberculosis could support personalized medicine leading to progress in cancer care, in particular the eradication of resistant CSCs and increased therapeutic efficiency in parallel with the diagnosis, detection and monitoring of treatment. “”
